FY2029 Earnings Forecast for IN8bio Issued By HC Wainwright

IN8bio, Inc. (NASDAQ:INAB) – Research analysts at HC Wainwright decreased their FY2029 EPS estimates for shares of IN8bio in a research note issued on Friday, March 13th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.15 per share for the year, down from their prior estimate of $0.25. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for IN8bio’s FY2030 earnings at $0.59 EPS.

Several other analysts have also recently issued reports on INAB. Zacks Research upgraded IN8bio to a “hold” rating in a research report on Thursday, January 15th. Weiss Ratings restated a “sell (e+)” rating on shares of IN8bio in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $4.00.

IN8bio Stock Up 9.0%

Shares of IN8bio stock opened at $2.06 on Monday. The company has a market capitalization of $20.13 million, a price-to-earnings ratio of -0.46 and a beta of 0.01. The stock’s 50-day simple moving average is $1.99 and its 200-day simple moving average is $1.98. IN8bio has a 52 week low of $1.17 and a 52 week high of $7.50.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.08).

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. increased its holdings in shares of IN8bio by 1,060.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock worth $2,231,000 after purchasing an additional 875,000 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of IN8bio by 381.6% in the fourth quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after buying an additional 724,637 shares in the last quarter. 683 Capital Management LLC bought a new position in IN8bio during the fourth quarter valued at approximately $1,696,000. Stonepine Capital Management LLC purchased a new position in IN8bio during the 2nd quarter valued at approximately $172,000. Finally, Two Sigma Investments LP purchased a new position in IN8bio during the 3rd quarter valued at approximately $107,000. Hedge funds and other institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.